1)Hamada S, et al:Nationwide epidemiological survey of acute pancreatitis in Japan. Pancreas 43:1244-1248, 2014
2)Satoh K, et al:Nationwide epidemiological survey of acute pancreatitis in Japan. Pancreas 40:503-507, 2011
3)Masamune A, et al:Clinical practice of acute pancreatitis in Japan;An analysis of nationwide epidemiological survey in 2016. Pancreatology 20:629-636, 2020
4)Lankisch PG, et al:The harmless acute pancreatitis score;A clinical algorithm for rapid initial stratification of nonsevere disease. Clin Gastroenterol Hepatol 7:702-705, 2009
5)急性膵炎診療ガイドライン2015改訂出版委員会,日本腹部救急医学会,厚生労働科学研究費補助金難治性膵疾患に関する調査班(編):急性膵炎診療ガイドライン2015 第4版,金原出版,2015
6)武田和憲,他:急性膵炎重症度判定基準最終改訂案の検証.厚生労働科学研究費補助金難治性疾患克服研究事業難治性膵疾患に関する調査研究,平成19年度総括・分担研究報告書,pp29-33, 2008
7)廣田衛久,他:日本の急性膵炎診療—全国調査2011より.膵臓30:123-136, 2015
8)Rau BM, et al:Early assessment of pancreatic infections and overall prognosis in severe acute pancreatitis by procalcitonin(PCT);A prospective international multicenter study. Ann Surg 245:745-754, 2007
9)Jie-Yao Li, et al:Enteral nutrition within 48 hours of admission improves clinical outcomes of acute pancreatitis by reducing complications;A meta-analysis. PLoS One 8:e64926, 2013
10)Hamada T, et al:Continuous regional arterial infusion for acute pancreatitis;A propensity score analysis using a nationwide administrative database. Crit Care 17:R214, 2013
11)Horibe M, et al:Continuous regional arterial infusion of protease inhibitors has no efficacy in the treatment of severe acute pancreatitis;A retrospective multicenter cohort study. Pancreas 46:510-517, 2017
12)Hirota M, et al:Continuous regional arterial infusion versus intravenous administration of the protease inhibitor nafamostat mesilate for predicted severe acute pancreatitis;A multicenter randomized, open-label, phase 2 trial. J Gastroenterol 55:342-352, 2020